ReviewBiochemistry research international2026
Chemerin Normal Function and Roles in Metabolic and Nonmetabolic Disorders: An Up-To-Date Comprehensive Review.
Review in Biochemistry research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemerin (retinoic acid receptor responder 2; RARRES2) is a secreted chemoattractant/adipokine that is expressed mainly in white adipose tissue, liver, and placenta and becomes bioactive after C-terminal proteolytic processing into isoforms with distinct activities. This review summarizes (i) chemerin biosynthesis, processing, receptors, and signaling (CMKLR1/ChemR23, GPR1, and CCRL2), (ii) key physiological roles in immune cell trafficking, adipogenesis, glucose and lipid homeostasis, and vascular biology, and (iii) current evidence linking chemerin signaling to major metabolic disorders and selected nonmetabolic diseases. Overall, circulating chemerin is frequently elevated in obesity, insulin resistance, metabolic syndrome, Type 2 diabetes, nonalcoholic fatty liver disease, and hypertension and often correlates with inflammatory markers; however, heterogeneity in study design, confounding, and limited isoform-specific measurements complicate causal inference and diagnostic validation. Beyond metabolism, chemerin signaling has been implicated in inflammatory conditions (e.g., rheumatoid arthritis and psoriasis) and multiple cancers with tumor type-specific pro- or antitumor effects. Standardized assays, isoform-resolved measurements, and prospective studies are needed to clarify disease mechanisms and determine the clinical utility of chemerin as a biomarker or target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.